摘要
目的分析恶性淋巴瘤自体造血干细胞移植治疗后的生存与预后因素。方法选取恶性淋巴瘤患者57例,统计生存率,收集患者治疗时间、国际预后指数(IPI)评分、乳酸脱氢酶(LHD)水平等资料,分析预后影响因素。结果57例恶性淋巴瘤患者,均获得有效随访,2年生存44例,死亡13例,生存率77.19%(44/57);IPI评分、有无骨髓侵犯、有无B症状、移植前状态、LDH水平、移植后有无巩固治疗是患者预后死亡的影响因素(P<0.05);logistic回归分析显示,IPI评分>2分、骨髓侵犯、B症状、移植前状态部分缓解、LDH水平>245 U/L、移植后未巩固治疗是患者预后死亡的危险因素(P<0.05)。结论IPI评分>2分、骨髓侵犯、B症状、移植前状态部分缓解、LDH水平>245 U/L、移植后未巩固治疗是恶性淋巴瘤患者自体造血干细胞移植治疗后死亡的危险因素,临床应据此实施干预措施,以降低死亡率,提高预后效果。
Objective To analyze the prognostic factors of patients with malignant lymphoma after autologous hematopoietic stem cell transplantation.Methods 57 patients with malignant lymphoma were selected,and the survival rate was analyzed.The treatment time,international prognostic index(IPI)score,lactate dehydrogenase(LHD)level and other data were collected,and the prognostic factors were analyzed.Results In this group,57 cases of malignant lymphoma patients were effectively followed up,44 cases survived for 2 years,13 cases died,the survival rate was 77.19%(44/57);IPI score,bone marrow invasion,B symptoms,pre transplant status,LDH level,consolidation treatment after transplantation were the influencing factors of prognosis and death(P<0.05);logistic regression analysis showed that IPI score>2,bone marrow invasion,B symptoms were the influencing factors of prognosis and death(P<0.05).Partial remission before transplantation,LDH level>245μ/L and no consolidation treatment after transplantation were the risk factors of prognosis death(P<0.05).Conclusion IPI score>2,bone marrow invasion,B symptoms,partial remission before transplantation,LDH level>245μ/L,and no consolidation therapy after transplantation are the risk factors of death in patients with malignant lymphoma after autologous hematopoietic stem cell transplantation.Clinical intervention measures should be implemented accordingly to reduce mortality and improve prognosis.
作者
叶媛媛
巴菲
王静静
YE Yuanyuan;BA Fei;WANG Jingjing(The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450000)
出处
《实用癌症杂志》
2022年第5期801-803,共3页
The Practical Journal of Cancer
基金
河南省医学科技攻关计划项目(编号:201830551)。
关键词
恶性淋巴瘤
自体造血干细胞移植
生存率
预后因素
Malignant lymphoma
Autologous hematopoietic stem cell transplantation
Survival rate
Prognostic factors
